Antiphospholipid Syndrome

被引:56
作者
George, Diane [1 ]
Erkan, Doruk [2 ]
机构
[1] Yale Univ, Dept Rheumatol, Sch Med, New Haven, CT 06520 USA
[2] Cornell Univ, Weill Med Coll, Hosp Special Surg, Barbara Volcker Ctr Women & Rheumat Dis, New York, NY 10021 USA
关键词
Antiphospholipid syndrome; Anticardiolipin antibodies; Lupus anticoagulant; Myocardial infarction; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERNATIONAL CONSENSUS STATEMENT; PRIMARY THROMBOSIS PREVENTION; ACUTE MYOCARDIAL-INFARCTION; LIBMAN-SACKS ENDOCARDITIS; CORONARY-ARTERY-DISEASE; ANTIBODY-SYNDROME; RISK-FACTORS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA;
D O I
10.1016/j.pcad.2009.06.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The antiphospholipid syndrome (APS) is an autoimmune systemic disease that is diagnosed when there is vascular thrombosis and/or pregnancy morbidity occurring with persistently positive antiphospholipid antibodies (aPL) (lupus anticoagulant test, anticardiolipin antibodies, and/or anti-β2-glycoprotein I antibodies). Although International APS Classification Criteria have been formulated to provide a uniform approach to APS research, aPL may cause a spectrum of clinical manifestations, some of which are not included in these criteria. The main aPL-related cardiac manifestations include valve abnormalities (vegetations and/or thickening), myocardial infarction (MI), intracardiac thrombi, and myocardial microthrombosis. In this article, we will review the definition, etiopathogenesis, clinical manifestations, diagnosis, and treatment of aPL-related clinical events with emphasis on cardiac manifestations. © 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:115 / 125
页数:11
相关论文
共 88 条
  • [1] Atherosclerosis in thrombotic primary antiphospholipid syndrome
    Ames, P. R. J.
    Antinolfi, I.
    Scenna, G.
    Gaeta, G.
    Margaglione, M.
    Margarita, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (04) : 537 - 542
  • [2] AMES PR, 2008, CLIN REV ALLERGY IMM
  • [3] Catastrophic antiphospholipid syndrome -: Clinical and laboratory features of 50 patients
    Asherson, RA
    Cervera, R
    Piette, JC
    Font, J
    Lie, JT
    Burcoglu, A
    Lim, K
    Muñoz-Rodríguez, FJ
    Levy, RA
    Boué, F
    Rossert, J
    Ingelmo, M
    [J]. MEDICINE, 1998, 77 (03) : 195 - 207
  • [4] Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
    Asherson, RA
    Cervera, R
    de Groot, PG
    Erkan, D
    Boffa, MC
    Piette, JC
    Khamashta, MA
    Shoenfeld, Y
    [J]. LUPUS, 2003, 12 (07) : 530 - 534
  • [5] AUGLIN P, 1994, CATHET CARDIOVASC DI, V31, P130
  • [6] BADAK G, 2002, J INVASIVE CARDIOL, V14, P194
  • [7] Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management
    Baker, William F., Jr.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 22 (01) : 155 - +
  • [8] Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery
    Berkun, Y
    Elami, A
    Meir, K
    Mevorach, D
    Naparstek, Y
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (02) : 414 - 420
  • [9] CATERINA R, 1989, AM J CARDIOL, V65, P922
  • [10] Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
    Cervera, R
    Piette, JC
    Font, J
    Khamashta, MA
    Cervera, R
    Piette, JC
    Font, J
    Khamashta, MA
    Shoenfeld, Y
    Camps, MT
    Jacobsen, S
    Lakos, G
    Tincani, A
    Kontopoulou-Griva, I
    Galeazzi, M
    Meroni, PL
    Derksen, RHWM
    de Groot, PG
    Gromnica-Ihle, E
    Baleva, M
    Mosca, M
    Bombardieri, S
    Houssiau, F
    Gris, JC
    Quéré, I
    Hachulla, E
    Vasconcelos, C
    Roch, B
    Fernández-Nebro, A
    Boffa, MC
    Hughes, GRV
    Ingelmo, M
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (04): : 1019 - 1027